Serotonin-specific reuptake inhibitors (SSRIs) are used to treat depressive disorders, which affect ∼10% of the population. Improving treatment requires a better understanding of the molecular pathways affected by these agents in different brain-cell populations. Addressing this issue has been difficult owing to the interconnectivity and complexity of brain-cell populations. Schmidt and colleagues overcame this challenge by using a transgenic mouse model involving a bacTRAP translational profiling approach to investigate the role of the p11 protein in responses to SSRIs. p11 is known to maintain serotonin receptors at the cell surface and to mediate antidepressant responses; some studies indicate that its expression is decreased in the brains of those with depression. The researchers tracked cells that were actively translating p11 protein and characterised their response to SSRIs. On treating mice with an SSRI, p11 expression was upregulated in a specific subset of cells in the frontal cortex, the layer 5 corticostriatal projection neurons, and resulted in induced expression of Htr4, encoding a serotonin receptor. Genetic ablation of p11 in this cell type prevented the upregulation of Htr4 and reduced the efficacy of SSRI treatment in mice. These data identify the cell type that is important in mediating the response to SSRIs, and provide unique mechanistic insight that might help to refine therapeutics for depression.
Antidepressant responses: key cell type identified Open Access
Antidepressant responses: key cell type identified. Dis Model Mech 1 July 2012; 5 (4): 415. doi:
Download citation file:
Advertisement
Cited by
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery

We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops

For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
Propose a new Workshop for 2027

We are currently seeking proposals for Workshops to be held in 2027. As one of the scientific organisers of a The Company of Biologists Workshop, your involvement will be focused on interdisciplinary, cutting-edge science and promoting new partnerships and collaborations. We focus on the logistics. Are you thinking about proposing a topic for one of our Workshops? Apply by Friday 30 May 2025.
Other journals from
The Company of Biologists